PL1833847T3 - Polipeptydy fuzyjne IGF-1 oraz ich zastosowanie terapeutyczne - Google Patents

Polipeptydy fuzyjne IGF-1 oraz ich zastosowanie terapeutyczne

Info

Publication number
PL1833847T3
PL1833847T3 PL06717668T PL06717668T PL1833847T3 PL 1833847 T3 PL1833847 T3 PL 1833847T3 PL 06717668 T PL06717668 T PL 06717668T PL 06717668 T PL06717668 T PL 06717668T PL 1833847 T3 PL1833847 T3 PL 1833847T3
Authority
PL
Poland
Prior art keywords
igf1
component
igf
fusion
fusion polypeptides
Prior art date
Application number
PL06717668T
Other languages
English (en)
Inventor
David J Glass
George D Yancopoulos
Thomas J Daly
Nicholas J Papadopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PL1833847T3 publication Critical patent/PL1833847T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
PL06717668T 2005-01-07 2006-01-06 Polipeptydy fuzyjne IGF-1 oraz ich zastosowanie terapeutyczne PL1833847T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US64222905P 2005-01-07 2005-01-07
US65658305P 2005-02-25 2005-02-25
EP06717668A EP1833847B1 (en) 2005-01-07 2006-01-06 Igf-1 fusion polypeptides and therapeutic uses thereof
PCT/US2006/000495 WO2006074390A2 (en) 2005-01-07 2006-01-06 Methods of treating obesity with combination therapeautics of igf-i fusion polypeptides

Publications (1)

Publication Number Publication Date
PL1833847T3 true PL1833847T3 (pl) 2011-12-30

Family

ID=42634965

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10007017T PL2241575T3 (pl) 2005-01-07 2006-01-06 Polipeptydy fuzyjne IGF-1 oraz ich zastosowania terapeutyczne
PL06717668T PL1833847T3 (pl) 2005-01-07 2006-01-06 Polipeptydy fuzyjne IGF-1 oraz ich zastosowanie terapeutyczne

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL10007017T PL2241575T3 (pl) 2005-01-07 2006-01-06 Polipeptydy fuzyjne IGF-1 oraz ich zastosowania terapeutyczne

Country Status (12)

Country Link
US (4) US7396918B2 (pl)
EP (2) EP1833847B1 (pl)
JP (1) JP4988599B2 (pl)
AT (1) ATE517120T1 (pl)
AU (1) AU2006203882B2 (pl)
CA (1) CA2594023C (pl)
DK (1) DK2241575T3 (pl)
ES (1) ES2541810T3 (pl)
HU (1) HUE027645T2 (pl)
PL (2) PL2241575T3 (pl)
PT (1) PT2241575E (pl)
WO (1) WO2006074390A2 (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521211B2 (en) * 2005-04-05 2009-04-21 Regeneron Pharmaceuticals, Inc IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof
KR101459789B1 (ko) 2006-06-09 2014-11-07 노파르티스 아게 안정화된 인슐린-유사 성장 인자 폴리펩티드
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
JP4958975B2 (ja) * 2006-08-31 2012-06-20 エフ．ホフマン−ラ ロシュ アーゲー インスリン様増殖因子ｉの製造方法
GB0715213D0 (en) * 2007-08-06 2007-09-12 Asterlon Ltd Igf-1
JP5627571B2 (ja) 2008-05-07 2014-11-19 バイオマリン ファーマシューティカル インコーポレイテッド リソソーム標的化ペプチドおよびその使用
WO2010088502A2 (en) * 2009-01-30 2010-08-05 The Regents Of The University Of California Insulin-like growth factor signaling and integrin
US7963705B2 (en) * 2009-02-24 2011-06-21 Avago Technologies Fiber Ip (Singapore) Pte. Ltd. Molded interconnect device (MID) optical connector with metal retaining clip
TWI490371B (zh) 2009-07-28 2015-07-01 Industrie De Nora Spa 電解應用上的電極及其製法以及在電極表面上陽極釋氧之電解法和電冶法
EP2571992B1 (en) 2010-05-21 2018-04-25 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
WO2012048330A2 (en) * 2010-10-08 2012-04-12 The Mclean Hospital Corporation Treatment of motor neuron disease
CN102618575A (zh) * 2011-09-16 2012-08-01 江苏普罗赛生物技术有限公司 哺乳动物细胞大规模生产重组人IGF1-Fc融合蛋白的实验技术
PL2935320T3 (pl) * 2012-12-18 2020-03-31 Novartis Ag Stabilizowane polipeptydy insulinopodobnego czynnika wzrostu
US10030063B2 (en) 2012-12-18 2018-07-24 Novartis Ag Production of therapeutic proteins in genetically modified mammalian cells
US10076384B2 (en) 2013-03-08 2018-09-18 Symple Surgical, Inc. Balloon catheter apparatus with microwave emitter
US20160271265A1 (en) 2013-10-02 2016-09-22 Novartis Ag Insulin-like growth factor mimetics for use in therapy
UY35874A (es) 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas
CN105992951A (zh) 2014-01-27 2016-10-05 诺华股份有限公司 预测肌萎缩的生物标志物、方法和用途
WO2016115171A1 (en) * 2015-01-16 2016-07-21 The Regents Of The University Of California Insulin-like growth factor 2 (igf2) signaling and modulation
CN108367048B (zh) 2015-10-02 2022-08-12 银溪制药股份有限公司 用于组织修复的双特异性治疗性蛋白质
MX2018013546A (es) * 2016-05-06 2019-04-22 Phasebio Pharmaceuticals Inc Proteinas de fusion de elp para liberacion controlada y sostenida.
WO2018189661A2 (en) * 2017-04-10 2018-10-18 Palti Yoram Prof Methods and compounds for treating diabetes
EP3453722A1 (en) * 2017-09-06 2019-03-13 Julius-Maximilians-Universität Würzburg Pharmaceuticals and devices for the covalent immobilization to the extracellular matrix by transglutaminase
CN107880133A (zh) * 2017-11-04 2018-04-06 海南大学 促皮质素与胰岛素样生长因子1融合蛋白及其制备方法
EP3569614A1 (en) * 2018-05-18 2019-11-20 Julius-Maximilians-Universität Würzburg Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
EP4606428A3 (en) * 2018-06-27 2025-11-05 Juvena Therapeutics, Inc. Heparin-associated polypeptides and uses thereof
KR20220077921A (ko) * 2019-10-10 2022-06-09 아미쿠스 세라퓨틱스, 인코포레이티드 변이체 igf2 작제물
CN115379850A (zh) 2019-12-24 2022-11-22 裘美娜治疗公司 再生性多肽及其用途
KR20230090336A (ko) * 2020-10-13 2023-06-21 베타바이브 리미티드 당뇨병 및 관련된 대사성 질환을 치료하기 위한 방법 및 화합물
WO2022271466A1 (en) 2021-06-21 2022-12-29 Juvena Therapeutics, Inc. Regenerative polypeptides and uses thereof
MX2024004398A (es) 2021-10-12 2024-07-09 Betavive Ltd Peptidos y fragmentos para tratar diabetes y enfermedades metabolicas asociadas.
CN119497630A (zh) * 2022-05-04 2025-02-21 免疫新炉有限公司 包含glp-1、免疫球蛋白fc和igf-1的融合蛋白及其用途
GB202216503D0 (en) * 2022-11-05 2022-12-21 Quadrucept Bio Ltd Non-human vertebrates & cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1990015142A1 (en) * 1989-06-09 1990-12-13 Gropep Pty. Ltd. Growth hormone fusion proteins
US5473051A (en) 1990-07-19 1995-12-05 The Scripps Research Institute Inhibition of Mac-1 receptor binding to fibrinogen using D30 homologs
WO1993023067A1 (en) 1992-05-08 1993-11-25 Thomas Jefferson University Igf-1 analogs
SE9402332D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab Igf-1
US5622932A (en) * 1995-05-05 1997-04-22 Eli Lilly And Company IGF-1 superagonists
US5814478A (en) 1995-12-15 1998-09-29 Regeneron Pharmaceuticals, Inc. Tyrosine kinase receptors and ligands
US6413740B1 (en) 1995-12-15 2002-07-02 Regeneron Pharmaceuticals, Inc. Tyrosine kinase receptors and ligands
AUPP298498A0 (en) 1998-04-17 1998-05-07 Gropep Pty Ltd Matrix binding factor
AU762351B2 (en) 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7355018B2 (en) 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
EP2173200B1 (en) 2007-07-23 2017-11-15 R.J.Reynolds Tobacco Company Smokeless tobacco compositions and methods for treating tobacco for use therein

Also Published As

Publication number Publication date
PT2241575E (pt) 2015-09-16
US7396918B2 (en) 2008-07-08
JP2008526233A (ja) 2008-07-24
HK1144684A1 (en) 2011-03-04
EP2241575B1 (en) 2015-06-24
CA2594023A1 (en) 2006-07-13
PL2241575T3 (pl) 2015-12-31
EP1833847B1 (en) 2011-07-20
WO2006074390A3 (en) 2007-01-11
ES2541810T3 (es) 2015-07-24
DK2241575T3 (en) 2015-08-24
HUE027645T2 (en) 2016-10-28
CA2594023C (en) 2015-07-14
WO2006074390A2 (en) 2006-07-13
AU2006203882B2 (en) 2011-05-12
EP1833847A2 (en) 2007-09-19
US20110020342A1 (en) 2011-01-27
US20120195896A1 (en) 2012-08-02
US7837999B2 (en) 2010-11-23
US20060166328A1 (en) 2006-07-27
AU2006203882A1 (en) 2006-07-13
US8158581B2 (en) 2012-04-17
ATE517120T1 (de) 2011-08-15
US8445434B2 (en) 2013-05-21
EP2241575A1 (en) 2010-10-20
US20090069235A1 (en) 2009-03-12
JP4988599B2 (ja) 2012-08-01

Similar Documents

Publication Publication Date Title
PL1833847T3 (pl) Polipeptydy fuzyjne IGF-1 oraz ich zastosowanie terapeutyczne
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
ZA200308589B (en) Recombinant fusion proteins and the trimers thereof.
IL152886A0 (en) B-7 related nucleic acids and polypeptides and pharmaceutical compositions containing the same
IL171926A0 (en) Glp-1 analog fusion proteins
EP2949658A3 (en) Peptides that specifically bind HGF receptor (cMet) and uses thereof
WO2004111217A3 (en) Variant pseudomonas polypeptides having a non-maltogenic exoamylase activity and their use in preparing food products
WO2005113606A3 (en) Fgf-21 fusion proteins
WO2005021592A3 (en) Enhancing the circulating half-life of interleukin-2 proteins
IL161016A (en) Polypeptides capable of ang-2 binding
EP1699920A4 (en) NEW RECOMBINANT PROTEINS WITH FREE N-TERMINAL THIOL
WO2004081026A3 (en) Polypeptides
MX353234B (es) Variantes de polipeptidos con función efectora alterada.
WO2003058203A3 (en) Extended glucagon-like peptide-1 analogs
WO2005077981A3 (en) Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
WO2008019368A3 (en) Albumin-insulin fusion proteins
CZ2014740A3 (pl)
AP2004003144A0 (en) Amino acids with affinity for the a2d-protein
WO1999003881A3 (fr) Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
WO2002060978A1 (en) Branched polyalkylene glycols
WO2007071692A3 (en) Immunogenic composition
WO2004087874A3 (en) Novel nucleic acids and polypeptides
WO2004043403A3 (en) Synthetic single domain polypeptides mimicking apolipoprotein e and methods of use
AP2006003544A0 (en) Amino acids with affinity for the alpha2delta-protein.
WO2000058465A3 (en) Flint polypeptide analogs